Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502085-24-00

Acronym

DC01EDO/1/22

Enrollment

Registered

2022-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

but it is a bioequivalence trial and the study population is healthy volunteers, Edoxaban is used as antithrombotic agents

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026